NASDAQ:CDXS

Codexis (CDXS) Stock Price, News & Analysis

Codexis logo
$1.15 +0.08 (+7.48%)
As of 11/18/2026 04:00 PM Eastern

About Codexis Stock (NASDAQ:CDXS)

Advanced

Key Stats

Today's Range
$1.06
▼
$1.18
50-Day Range
$0.96
▼
$1.48
52-Week Range
$0.90
▼
$2.98
Volume
1.47 million shs
Average Volume
950,720 shs
Market Capitalization
$126.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Hold

Company Overview

Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes.

Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.

The company works with pharmaceutical and biotechnology partners to develop and apply its technologies in manufacturing. Its business centers on improving production processes through enzyme engineering and biocatalysis.

AI Generated. May Contain Errors.

Codexis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

CDXS MarketRank™: 
3.221568359105 of 5 stars

Codexis scored higher than 64% of companies evaluated by MarketBeat, and ranked 449th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Codexis has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Codexis has a consensus price target of $6.00, representing about 421.7% upside from its current price of $1.15.

  • Amount of Analyst Coverage

    Codexis has only been the subject of 2 research reports in the past 90 days.

  • Read more about Codexis' stock forecast and price target.
  • Earnings Growth

    Earnings for Codexis are expected to grow in the coming year, from ($0.37) to ($0.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Codexis is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Codexis is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Codexis has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.16% of the float of Codexis has been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 4.89.
  • Change versus previous month

    Short interest in Codexis has recently decreased by 11.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Codexis does not currently pay a dividend.

  • Dividend Growth

    Codexis does not have a long track record of dividend growth.

  • News Sentiment

    Codexis has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Codexis this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for CDXS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Codexis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,373.00 in company stock.

  • Percentage Held by Insiders

    3.50% of the stock of Codexis is held by insiders.

  • Percentage Held by Institutions

    78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Codexis' insider trading history.
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CDXS Stock News Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Codexis, Inc. (CDXS)
Codexis (NASDAQ:CDXS) Earns Overweight Rating from Stephens
Codexis (NASDAQ:CDXS) Upgraded at Wall Street Zen
Codexis (CDXS) Q3 2026 Earnings Call Transcript
Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript
See More Headlines

CDXS Stock Analysis - Frequently Asked Questions

Codexis' stock was trading at $1.63 at the beginning of 2026. Since then, CDXS stock has decreased by 29.4% and is now trading at $1.15.

Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, November, 12th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The biotechnology company had revenue of $19.26 million for the quarter, compared to analysts' expectations of $18.72 million. Codexis had a negative trailing twelve-month return on equity of 43.24% and a negative net margin of 21.77%.
Read the conference call transcript
.

Codexis (CDXS) raised $0 in an initial public offering on Thursday, April 22nd 2010. The company issued 0 shares at a price of $0.00-$13.00 per share.

Top institutional shareholders of Codexis include Aberdeen Group plc (9.86%), Nantahala Capital Management LLC (2.37%), State Street Corp (1.49%) and Private Advisor Group LLC (1.10%). Insiders that own company stock include Opaleye Management Inc, Alison Moore, Stefan Lutz, Vre Raymond De and Georgia Erbez.
View institutional ownership trends
.

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Micron Technology (MU), NIO (NIO), Tesla (TSLA), CRISPR Therapeutics (CRSP) and Cisco Systems (CSCO).

Company Calendar

Last Earnings
11/12/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:CDXS
CIK
1200375
Employees
146
Year Founded
2002

Price Target and Rating

High Price Target
$8.00
Low Price Target
$5.00
Potential Upside/Downside
+421.7%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.97 million
Net Margins
-21.77%
Pretax Margin
-21.69%
Return on Equity
-43.24%
Return on Assets
-14.21%

Debt

Debt-to-Equity Ratio
0.58
Current Ratio
2.81
Quick Ratio
2.99

Sales & Book Value

Annual Sales
$88.34 million
Price / Sales
1.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.47 per share
Price / Book
2.45

Miscellaneous

Outstanding Shares
109,598,000
Free Float
105,762,000
Market Cap
$126.04 million
Optionable
Optionable
Beta
2.38

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:CDXS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners